Target Product Profiles, preferred product characteristics and target regimen profiles

 

What is a product profile?

WHO product profiles are a planning tool to guide health product research and development (R&D). They specify the intended use, target populations, and desired attributes of products; support evidence generation for regulatory submissions; and help create alignment on R&D targets and priorities for funders and developers.

 

Benefits of WHO product profiles

WHO product profiles have particular requirements and specific objectives:

  • Enabling developers and funders to align their product pipeline with public health priorities
  • Integrating implementation and end-user needs and considerations into product R&D phases with a specific focus on the most vulnerable populations
  • Demonstrating likelihood of policy development and thus product purchasing
  • De-risking investment in health product R&D
  • Supporting ethical R&D for product development
  • Facilitating ease of product review and accelerating guideline development

 

Graphic illustrating the benefits of WHO Product profiles

Types of WHO product profiles

  1. Preferred product characteristics (PPCs):
    • Applicable to product classes of priority with a pipeline in early development
    • Provide strategic guidance and higher-level considerations
    • Specify WHO preferences but not minimum acceptable criteria
  2. Target product profiles (TPPs):
    • Describe optimal characteristics for health product
    • Include minimal essential characteristics for product usability
  3. Target regimen profiles (TRPs):
    • Applicable to certain disease areas (e.g., tuberculosis) requiring multiple therapeutics to be combined into treatment regimens.

     

Content and structure of WHO product profile documents

WHO product profiles describe the (a) preferred and (b) minimally acceptable profiles for vaccines, other preventive methods such as vector control, therapeutics, diagnostics or medical devices. The broad sections of TPP and PPC documents are as follows:

  1. Overview:
    • Background and specified purpose statement
    • Rationale for the document
  2. Methods:
    • Describe process used for product profile development
  3. Profile (some compulsory headings) and clarifying text as needed.
    • TPPs contain minimal and optimal characteristics; PPCs should not contain minimal acceptable criteria
  4. Supporting narrative sections

In some cases, an external TPP may be adapted and redeveloped into a WHO-compliant TPP. A specific pathway is available for these products.

 

Graphic illustrating the TPP development process
 

Explore the WHO TPP Directory (TPPD)

  • An essential tool for realizing universal health coverage, the WHO TPPD promotes R&D to combat diseases affecting neglected populations and global health threats.
  • A searchable database of key characteristics desired for health products, including medicines, vaccines, diagnostics and medical equipment
  • Links provided to access the full product profile document where publicly available

 

For more information

Related publications

All
Landscape analysis of primary health care research in South, East Asia and the Pacific: policy brief

Nearly half of PHC studies focused on service delivery while financing has the least attention. In terms of health programme focus, NCDs and injuries accounted...

WHO Technical Advisory Group on the responsible use of the life sciences and dual-use research: report of the meeting, 22 January 2025

The World Health Organization (WHO) Technical Advisory Group on the Responsible Use of the Life Sciences and Dual-Use Research (TAG-RULS DUR) was established...

Global action plan for clinical trial ecosystem strengthening

This plan sets out nine key action areas to improve innovation, design, conduct, and oversight of clinical trials. It supports implementation of WHO’s...

WHO Technical Advisory Group on the responsible use of the life sciences and dual-use research: report of the meeting, 30 October 2024

The World Health Organization (WHO) Technical Advisory Group on the Responsible Use of the Life Sciences and Dual-Use Research (TAG-RULS DUR) was established...

Clinical research landscape of monoclonal antibodies

Monoclonal antibodies (mAbs) are artificial proteins that mimic the body’s natural defences and represent an important medical innovation in modern...